Takeda invests in Zelluna Immunotherapy

Zelluna Immunotherapy, a Norwegian company developing allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer, has announced an investment from Takeda Ventures.

The funds will enable the advancement of a lead TCR-NK product through manufacturing to clinical trial application (CTA) and Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna’s platform with additional programs reaching the preclinical stage.

"As part of our R&D partnership strategy, we invest in early-stage opportunities that complement Takeda’s pipeline and products,” said Miles Gerson, senior investment director and partner at Takeda Ventures. "Zelluna’s novel approach to TCR based cell therapies aligns with Takeda’s ambition to broaden the impact of immunotherapies by leveraging the power of the innate immune system. We are pleased to support Zelluna as they look to progress their TCR-NK platform toward the clinic,” he added.